BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

s Keytruda. BioNTech secured a leading candidate in the race one year ago by paying Biotheus $55 million upfront for the ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

去年11月，BioNTech和普米斯生物联合开发了一款名为BNT327的“双特异性抗体”药物。BioNTech后来预付了5500万美元，并承诺支付高达10亿美元的里程碑付款，以确保大中华区以外的权益。

And, in non-small cell lung cancer with specific EGFR mutations, MI Cancer Seek can be used with approved tyrosine kinase ...

It said it saw BNT327’s dual-target approach as a significant advancement over single-action therapies like Merck’s Keytruda ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...